AVROBIO Inc Stock News

Here is how AVROBIO, Inc. (AVRO) and Crinetics Pharmaceuticals, Inc. (CRNX) have performed compared to their sector so far this year.

Here is how AVROBIO, Inc. (AVRO) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

Here is how AVROBIO, Inc. (AVRO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.

After monetizing one of its pipeline candidates, Avrobio has cash well in excess of its market cap. The company announced its search for strategic alternatives recently. The process could close its va

AVROBIO (AVRO) announces its decision to halt all development programs in its quest to explore strategic alternatives. The stock of the company surges 46% in response on Wednesday.

Penny stocks continue to offer incredible opportunities for investors in 2023. As high-growth, micro-cap equities, they have the potential to outperform traditional stocks, particularly given their in

AVROBIO (NASDAQ: AVRO ) stock is seeing massive gains on Monday as the company sells one of its gene therapies to Novartis (NYSE: NVS ). This deal has Novartis agreeing to pay $87.5 million in cash to

Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different

AVROBIO Inc (NASDAQ: AVRO) reported new interim data from the Phase 1/2 gene therapy trial of AVR-RD-04 for cystinosis. Cystinosis is a condition characterized by the accumulation of the amino acid

In the latest trading session, 5.01 million AVROBIO Inc. (NASDAQ:AVRO) shares changed hands as the company’s beta touched 1.62. With the company’s most recent per share price at $1.72 changed hands at -$0.04 or -2.56% at last look, the market valuation stands at $74.69M. AVRO’s current price is a discount, trading about -1058.14% off its … AVROBIO Inc. (NASDAQ: AVRO) Is Becoming An Interest-Losing Stock With A -2.56% Decline Read More »

Avrobio Inc''s (NASDAQ: AVRO ) gene therapy for a rare lysosomal storage disorder showed potential durability in the first three patients more than one year after infusion. The data comes from a Phase 1/2 trial testing the safety and efficacy of AVR-RD-04 for cystinosis who had previously been given cysteamine, which is a standard treatment that reduces the buildup of cystine crystals in … Full story available on Benzinga.com

AVROBIO (AVRO) is trading ~11% higher in the pre-market on Wednesday after the company reported data from an ongoing Phase 1/2 clinical trial for AVR-RD-04 in adults…

Avrobio Inc's AVRO gene therapy for a rare lysosomal storage disorder showed potential durability in the first three patients more than one year after infusion. Get the Inside Access Traders Are Us

What you need to know about trading penny stocks today The post Trading Penny Stocks? Top Stock Market News for February 9th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information |